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Abstract
Soy, which contains a form of phytoestrogen known as isoflavones, impacts the biological activity of humans at all stages. There
are many aspects to consider when determining whether soy is beneficial. Since the hormone estrogen plays a significant role
in maintaining the biochemical and homeostatic conditions of an individual, it follows that the disruption of estrogenic levels can
be detrimental. There are many hormone- dependent diseases that can be linked to one’s diet, and the possibility of utilizing
phytoestrogens, such as soy, to prevent or control hormonal irregularities is compelling. This paper explores the effects that phytoestrogens, specifically soy, can have at various stages of hormonal progression.
Introduction
Recently, soy has been garnering attention for its estrogen-like qualities. One group of chemicals found in soy are
phytoestrogens, a non-steroidal class of estrogens. Of the
numerous phytoestrogens, the study of the role of isoflavones has been isolated because of their high concentration in soy. Crucial to understanding soy’s “estrogen-like”
qualities is understanding isoflavones’ chemical makeup.
In soy specifically, isoflavones present as glycosides, which
are bound to sugar molecules. When the isoflavone glycosides are digested and released, the isoflavone presents
as aglycones. This includes compounds such as genistein,
daidzein, and glycitein.

Figure 1. Chemical structures of 17β-estradiol (A) and genistein (B)
(Thangavel, 2019)

Structurally, these isoflavones are similar to a form of
estrogen, 17β-estradiol, as shown (fig, 1). The phenolic
ring on the isoflavones is a crucial part of its structure
which chemically allows the phytoestrogen to attach to
estrogen receptors, thus promoting “estrogen-like” activity. Once the isoflavone is bound to an estrogen-receptor complex, the phytoestrogen can act as an estrogen
agonist or antagonist. Based on various factors, such as
the concentration levels of the phytoestrogen and endogenous estrogen, the specificity of the receptor, and the
particular tissue that the phytoestrogen is targeting, the
soy will either act as an estrogen inhibitor or stimulant.
This holds promise as a physiologically beneficial method of regulating hormonal abnormalities. Dietary estrogen has shown potential in alleviating postmenopausal
symptoms, reducing the risk of breast cancer, and bone
resorption. However, soy is dosage- dependent, and a
high intake of soy in infancy may lead to some physical
signs of sexual maturation at a young age. Soy has also
been a contributing factor for both very early and late
menarche. There is a concern for early maturation, as it
can cause hormone- related cancers such as breast cancer. Therefore, the consumption of soy that leads to the

binding of isoflavones to sex-hormone binding globulins
(SHBG) necessitates much research to determine all possible outcomes (Setchell, 1998).
Methods
The following research is based on the analysis of numerous articles from various databases, that include but are
not limited to The Touro College Library online, PubMed,
and ProQuest. The National Center for Biotechnology
(NCBI), and BioMed Central (BMC) were additional
sources of data as well.
Discussion
Infants
Soy- based infant formula (SBIF) has been used for over
100 years. SBIFs were developed as an alternative to
cow’s milk-based formula for infants that were lactose intolerant or required vegan replacement. Recent data has
shown that SBIF is used by approximately 20%-25% of
Americans. SBIF has a high concentration of isoflavones;
the concentration levels vary from 32 to 47 mg isoflavones/L of formula. According to research, “infants fed
SBIF are exposed to a 6–11 fold higher level of isoflavones
on a body weight basis than adults. Additionally, circulating isoflavone levels of these infants were 13,000–22,000
times greater than circulating levels of 17-β-estradiol.”
(Dinsdale et al., 2010) The effect of an infant consuming
and absorbing this high of a dosage of an estrogeniclike substance can have long-term consequences. This is
because SBIF is primarily used from birth to one years
old, which is a stage of development that is “particularly sensitive to dietary and environmental compounds.”
However, it is exceedingly difficult to track soy formula’s precise long-term effects on reproductive health. In
order to so, all participants must be monitored before
reaching puberty and all through the child-bearing years;
this would allow the possible differences in reproductive
health and organ development to be determined. Since
that would require long-term compliance, a retrospective approach has been taken to analyze the effects on
those who consumed SBIF. However, as a retrospective
study, there are the limitations of recall bias and environmental differences, such as smoking, physical activity and
history of diseases, which make it difficult to determine
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the accuracy of the results. No reports were given of
long-term adverse effects for the male infants fed SBIF. At
six months of age, female infants were reported to have
increased vaginal cell maturation. There did not seem to
be any vaginal discharge or breast development that was
out of the ordinary. However, when children at two- years
-old were still fed SBIF, there was an increase in the pervasiveness of breast tissue development in these children.
Furthermore, the study reported that formula feeding
in general, whether soy- or cow’s milk-based, can cause
greater ovarian volume, an increase in the numbers of
ovarian cysts per ovary, and lower testicular volume.
On the other hand, SBIF and soy in general seem to prevent breast cancer. High levels of isoflavone enhance differentiation of the mammary glands, which leads to greater
protection against chemically-induced mammary cancer.
This was proven through a study in which genistein treatment was given, resulting in “fewer terminal end buds and
advanced development and ductal elongation.” As the least
mature terminal ductal structures, it follows that terminal
end buds are the most susceptible to possible carcinogens.
Therefore, reducing the number of terminal end buds can
lead to lower incidences of breast cancer. This is due to
the fact that, “Part of the terminal end bud differentiates
according to each estrous cycle, giving rise to alveolar buds
that consist of lobule structures that are more mature and
less susceptible to chemical carcinogens.” This treatment
of genistein increased the number of lobules, which shows
that there is a potential protective effect against mammary cancer. The exact mechanism in which genistein affects
mammary gland development is unclear; however, according to these findings, genistein clearly displayed estrogeniclike behavior (Dinsdale et al., 2010).

Further studies show that high soy exposure during the
prenatal and infant stages can cause early onset puberty,
specifically menarche. Early menarche (≤10-11 years old)
is just one of the factors that are considered when determining whether a female reached puberty; however, it
is the most commonly used benchmark. There are many
issues associated with early development, such as adult
obesity, type 2 diabetes, metabolic syndrome, and other
markers of cardiovascular disease. A study was done to
determine the various factors involved in early menarche,
soy being among them. The Sister Study enrolled 50,884
American and Puerto Rican women between the ages of
35-74.The study was interested in finding whether certain
early-life exposures are related to the health conditions
mentioned above.The authors conducted interviews that
included a comprehensive family medical history. Anyone
that did not have a mother to relate the early life events
was excluded. The study combined those that said they
“definitely” or “probably” had feeding exposures into one
category, and those that responded that they “definitely
did not” and “probably did not,” into another category.
Race/ethnicity, maternal age menarche, birth weight, birth
decade, and childhood family income were also factored
into the results. Results showed that, “The frequency of
early menarche (≤11 years) was 20%, with 7% reporting
menarche at 10 years of age or younger.The frequency of
late menarche (≥14 years) was 24%, with 10% reporting
menarche at 15 years of age or older.”
The table above shows that SBIF can cause both early
(≤10 years old) and very late menarche (≥15 years old).
Although age at menarche is not the only sign of pubertal development, it is a key component; therefore, these
studies are an important resource to tracking pubertal
development. These findings are
Table 1
consistent with animal data that
proves that the dose of genistein
impacts whether early or late
puberty will occur. “Mice administered a higher dose of genistein
had a delayed vaginal opening
(marker of puberty), while mice
given a lower dose had an accelerated vaginal opening. Neonatal
administration of genistein to
mice has also produced other
alterations in reproductive characteristics, including changes in
estrous cycles, early reproductive
Relative Risk Ratios for Early and Late Menarche in Association with Early-Life Exposures in
senescence, and decreased fertilWomen Aged 35 to 59 years at Baseline in the Sister Study, 2003-2009 (n = 33,501)
ity.” In other words, the effects
(D’Aloisio et al., 2013)
of neonatal administration of
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genistein were greater than when genistein was administered to older mice. This makes sense considering that
soy formula delivers a high dosage of its estrogenic components to infants “per unit body weight.” Additionally,
genistein is highly digestible and has been found in high
concentrations in infants’ urine and plasma. Thus, maintaining that the genistein can influence the estrogeniclike effect on these infants (D’Aloisio et al., 2013).
Furthermore, while there is no evidence that SBIF
directly effects reproduction, SBIF does exert its influence on the menstrual cycle. Women who were given
soy formula as infants reported prolonged menstruation
and more discomfort. With all this data, the question of
whether or not soy formula is safe remains. Many countries have regulations on the use of SBIF. For instance, in
Europe, SBIF is a prescribed product. However, despite
these regulations, there is a large percentage of infants
each year that are fed SBIF (Dinsdale et al., 2010).

diagnosis of diabetes. A lab assessment revealed that he
had low free and total testosterone levels, with increased
levels of dehydroepiandrosterone (DHEA). His symptoms
began after he started his vegan diet, which included
products such as soy milk, soy cookies, tofu, soy sauce,
soy nuts, and soybeans. Beforehand, he had been consuming the average American 2,000- kcal diet. After stopping
his vegan and soy diet, his symptoms improved over the
course of 12 months. These improvements were consistent with the gradual normalization of his testosterone
and DHEA levels. The table below shows the progression
of the patient’s levels of total and free testosterone, as
well as the levels of DHEA normalizing over a period.
The insufficient blood levels of free testosterone, which
causes hypogonadism and erectile dysfunction, normalized after the cessation of the soy diet, indicating that the
high levels isoflavones may have been the cause.
The correlation between testosterone and soy may be
explained by research on animals. “Animal studies have
Male Reproduction
shown that isoflavones can bind to the estrogen receptor
Considering isoflavones’ estrogenic qualities, it follows
expressed by testosterone-producing Leydig cells, therethat there can be estrogenic effects on males that conby affecting Leydig cell differentiation and testosterone
sume high concentrations of soy. There are not many
production, which ultimately leads to reproductive toxcases reported of soy stimulating feminizing effects on
icity.” Therefore, consuming high levels of isoflavones can
men, such as gynecomastia. However, a study was done
stimulate similar bioactivity in males. Another possibility
on an instance of hypogonadism and erectile dysfunction
is that the estrogen- like isoflavones can cause a negathat was linked to high intake of soy. A 19-year-old male
tive feedback mechanism that interferes with the DHEA
that was recently diagnosed with type 1 diabetes began
conversion to testosterone. As the DHEA converting
experiencing complete loss of libido and erectile dysenzymes 3-b-hydroxysteroid dehydrogenase and 17-b-hyfunction. Until the previous year, he had been in perfect
droxysteroid dehydrogenase are inhibited through the
health. He stated he had a heterosexual preference, was
isoflavones genistein and daidzein present in soybean, the
sexually active, had satisfactory libido, denied any history
negative feedback is facilitated. The inhibition is what can
of orchitis or undescended testicles, had normal testiclead to a decrease in testosterone. Another possible way
ular size, and body hair pattern. Additionally, he denied
in which the isoflavones decreased the free testosterone
any androgen abuse, hormonal medication, drug abuse, or
levels can be through the increase of the sex hormonepsychiatric disorders. He had never had a sexually transbinding globulin (SHBG), which is produced by the estromitted disease, no visual or muscular mass and strength
genic activities of isoflavones. The increase of SHBG leads
changes, and no headaches. The one notable difference in
to more binding of the SHBG with the total circulating
his lifestyle was that he had taken on a vegan diet, which
testosterone, which means there will be less free testosincluded high levels of soy (360 mg/day), due to his recent
terone; this also further explains why the total circulating testosterone levels were within
Table 2
normal range (table 2). However,
because there were missing SHBG
measurements during the vegan diet,
this hypothesis cannot be confirmed.
There were nine more studies done
in which the highest level of isoflavone concentration given was 139
mg/d, as opposed to the 360 mg/d
given in this study. As this was the
only study done that there was
(Partial) Hormone profile at cessation of vegan diet and during 2-y follow-up (Siepmann et al., 2011) clearly a testosterone decrease with
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the consumption of soy, researchers speculate that there
is an “isoflavone intake threshold” for symptoms to occur.
There is also the possibility that since the composition
of soy products has evolved over the years, there might
have been differences in the soy products of the previous studies. While further studies are necessary, this case
report successfully indicates that a high consumption of
isoflavones is related to hypogonadism and decreased
free testosterone (Siepmann et al., 2011).
Menopause
Phyto-estrogens that are administered in an environment
that has a high concentration of endogenous estradiol
have an antagonist effect on the estrogen receptors. In
that case, the isoflavones act as an inhibitor. However,
when there is a decrease of endogenous estrogen, such
as hypogonadism and menopause, an administration of
isoflavones will stimulate estrogenic bioactivity (Casini et
al., 2006). Menopause symbolizes the end of a women’s
reproductive life and is characterized by the cessation
of menstrual periods for 12 consecutive months, which
normally occurs between 45-55 years of age. Aside from
the cessation of menstrual periods, there are additional
symptoms, such as hormonal disturbances, hot flashes,
night sweats, sleeping disorders, vaginal dryness, joint pain,
mood swings, reduced bone density, and cardiovascular
disease (Sunita et al., 2011). This mainly occurs because
the menopause transition results in estrogen deficiency.
Estrogen regulates appetite, cholesterol levels, carbohydrate and lipid metabolism, and protects bone. Therefore,
when a woman is estrogen- deficient, the possibility of
obesity, osteoporosis, and cardiovascular disease is more
prevalent. To combat the hormonal imbalance, there are
various forms of hormone replacement therapies (HRT).
However, there are a host of issues with the with the
HRT available, because the treatments available can cause
diseases such as thromboembolism, uterine hyperplasia,
uterine cancer, increased risk of breast, ovarian, and endometrial cancers, coronary heart disease, and stroke.
Therefore, in more recent years women have been turning toward more natural methods of HRT, such as soy,
to alleviate menopausal symptoms. Genistein promotes
an inhibitory effect on many of the common menopausal symptoms. “It should be noted that genistein acts on
various molecular pathways to emulate the effects of estrogens, without being known to elicit any life-threatening
adverse effects.” There have been studies done to determine how effective this form of therapy may be; however, this is still a relatively recent discovery and there are
many aspects that need further exploration (Thangavel
et al., 2019).
20

The Asian diet is heavenly concentrated with soy, relative to the European and American diet. Statistically, only
20%-25% of Asian postmenopausal women experience
hot flashes, whereas 70%-80% of European and Latin
American postmenopausal women complain of hot flashes. Since these hot flashes are one of the main postmenopausal symptoms that women seek HRT for, researchers
were compelled to discover what caused Asian women
to have a lower incidence rate (Thangavel et al., 2019).
There are a few studies that have reported the effectiveness of genistein in treating hot flashes. A study was done
on Japanese women specifically, comparing soy intake to
incidences of hot flashes. This study was conducted over
six years, in which it was shown that the consumption
of soy reduced the hot flashes considerably. Even at the
lowest concentration of isoflavones (75.2- 115.9 g/day),
the hot flashes were lower, but the response rate was
definitely more successful in the women that consumed
higher levels of soy (Nagata et al., 2001). Another study
was done on menopausal women and found that the “administration of 30 mg of genistein for 12 weeks reduced
hot flashes by 51% (9.4–4.7/day), whereas the placebo
group experienced only a 27% reduction (9.9–7.1/day).”
(Braxas et al., 2019) Furthermore, a randomized trial was
conducted in which hot flashes were alleviated by the
consumption of 54 mg/day over the course of a year. The
mechanism in which genistein can inhibit the hot flashes is
unclear. However, researchers speculate that the genistein
diffuses through the cell’s lipid bilayer “due to genistein
being an effective ER (estrogen receptor) modulator.”
This will set off the mRNA synthesis and production
of tissue-specific proteins (Crisafulli et al., 2004). While
there is no definite conclusion as to why genistein inhibits
hot flashes, it seems to be a successful method based on
the results of the numerous studies above.
Another effect that occurs because of estrogen depletion is the change in metabolism, such as the slowing down
of the body’s ability to metabolize carbohydrates and lipids.
Consequently, women in the menopause stage are susceptible to weight gain. Genistein was found to stimulate a
metabolic rate of carbohydrates and lipids to help prevent
weight gain. This occurs because genistein regulates adipose tissue by restricting lipogenesis and enhancing lipolysis in adipocytes (Szkudelska et al., 2007). Furthermore,
phytoestrogen treatment “reduced obesity markers, such
as total cholesterol and low-density lipoprotein (LDL) cholesterol.” These are common markers that are associated
with obesity and cardiovascular health (Jayagopal et al.,
2002). Additionally, another study reported that after 6 to
12 months of 54 mg/day of genistein treatment there was a
significant reduction in triglycerides, total cholesterol, and
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LDL-cholesterol (Squadrito et al., 2013). Conclusively, soy
treatment can potentially improve cardiovascular health
and prevent obesity.
There seems to be a positive correlation between a
soy rich diet and the inhibition of cancers, specifically
breast cancer. SBIF can inhibit breast cancer as well. Most
of the studies compared the association of soy-rich diet
with reduced breast cancer in Asian women, compared to
those in the Western world. In one case, an Asian woman
who migrated to a Western country showed an increased
risk for cancer. The risk of breast cancer increases with
age, and this form of cancer has become one of the most
common forms of cancer affecting women. As the common forms of HRT are known to increase the risk of
developing breast cancer, natural methods are a compelling substitute. Genistein, the form of isoflavone that is
the most abundant in soy, has shown anticancer properties in preclinical trials, thereby opening the option of
attempting clinical trials. Since this bioactive compound,
soy, induces apoptosis in various cancer cell lines, such as
HepG2 and Hep3B, in- vitro studies have proven the efficacy of genistein as a promising chemotherapeutic agent
against cancer. Table 3 summarizes some of the common
menopausal symptoms and how genistein can alleviate
the symptoms (Thangavel et al., 2019).
Table 3

In addition to the diseases mentioned above, osteoporosis is another disease that postmenopausal women
are prone to. Since estrogen has bone- protecting properties, it follows that a lack of estrogen puts menopausal
women at risk of developing osteoporosis. Soy has been

reported to reduce the risk of osteoporosis in peri- and
post-menopausal women. A study was done examining
the effects of a heavy soy diet on the overall bone density and strength of postmenopausal women. Eighty-seven
women were eligible and were assigned to consume soy
or control foods daily for one year. “Bone mineral density
(BMD) and bone mineral content (BMC) of the whole
body, lumbar (L1-L4), and total hip were measured using
dual energy x-ray absorptiometry at baseline and after
one year (Arjmandi et al., 2005).” Additionally, urine and
blood markers of bone metabolism were assessed. Of
the eighty-seven women, sixty-two completed the oneyear long study. Results showed that whole body and
lumbar BMD and BMC decreased in both the soy and
control groups. However, the total hip BMD and BMC
did not change in either group. “Both treatments positively affected markers of bone formation as indicated
by increased serum bone specific alkaline phosphatase
(BSAP) activity, insulin-like growth factor-I (IGF-I), and
osteocalcin (BSAP: 27.8 and 25.8%, IGF-I: 12.8 and 26.3%,
osteocalcin: 95.2 and 103.4% for control and soy groups,
respectively).” (Arjmandi et al., 2005) Neither group had
any effect on urinary deoxypyridinoline excretion, which
is a marker of bone resorption. However, according to
epidemiological data, populations with soy rich diets, such
as the Asians, do have a lower incidence of
osteoporotic fractures. On the other hand,
there are numerous factors that contribute
to skeletal health; therefore, the credit of the
lower rates of fractures in these populations
cannot be fully attributed to soy consumption.
There are a number of animal studies that did
show how isoflavones positively influenced
BMD. However, when it comes to human
studies there are a limited number of studies
that examined the effects of soy on bone. A
study was set up in which the identity of the
individual treatments was only revealed after
the analysis was complete, to keep the results
as accurate as possible. Compliance of the
participants was measured based on whether
participants recorded the amount of soy they
consumed and if they returned the uneaten
food to the study site to be tallied. This study
did not show that soy protein alone can substantially prevent bone loss. However, another
study did indicate that a consumption of 40 mg/day to 80
mg/day for a year resulted in positive increases in BMC
of the hip of the women who are at least four years post
menopause. Additionally, these women were of low body
weight or had low levels of dietary calcium. In the study
21

Anne Roberts

done in which there was no substantial effect of soy on
reversing bone loss, most of the participants were four
years post-menopause; however, many did not have low
body weight or calcium intake. Therefore, it is possible
that the differences in these factors are what created the
discrepancy of the observed results of the bone (Chen
et al., 2004). As far as which form of isoflavones is the
most beneficial when it comes to affecting the bone, according to studies genistein is the single isoflavone with
the greatest effect. A study demonstrated that genistein
at a dose of 54 mg/d combined with HRT increased BMD
in early postmenopausal women. Genistein was proven
to increase the BMD of the femoral neck by 3.6% and
the lumbar spine by 3.0%. HRT increased femoral neck
and lumbar spine BMD by 2.4 and 3.8%. The researchers
speculated that the genistein “reduces bone resorption
markers” and “enhances new bone formation parameters.” As a result, there is a bone mass net gain (Morabito
et al., 2002). According to the circulating sex hormone
levels that were assessed after examining the changes in
the participants after a year, the soy did not produce any
estrogenic effects. However, the soy did decrease SHBG
concentrations, which increases the availability of circulating estrogens. Therefore, the soy did affect estrogen
levels, even though it may not have directly exhibited estrogenic qualities. However, to confirm this, it would be
necessary to measure the endogenous estradiol that is
circulating. While there are certainly a number of studies
that show correlation between bone protection and soy,
there are still too many factors that require closer examination (Arjmandi et al., 2005).
Conclusion
Many soy- related articles are published annually; however, there are still numerous questions that require further
exploration. Questions include whether SBIF is indeed
harmful or not, how effective of an HRT is soy when it
comes to menopausal symptoms, whether the effect of
isoflavones on bone is transitory, and whether soy isoflavones and lower doses of antiresorptive agents can
prevent postmenopausal bone mineral loss. In the United
States, advisory groups gave their recommendation
regarding the safety of soy infant formula. “The North
America Committee on American Academy of Pediatrics
recommends soy formula only for infants with galactosemia or hereditary lactase deficiency and mentions that
soy formula might be useful for families wishing to avoid
formula containing animal products.” (Adgent et al., 2018)
While high consumption may not be advisable for infants,
Asian postmenopausal women with soy rich diets benefit
from the isoflavones as shown by the studies mentioned
22

above. The efficacy of soy and its isoflavones as an alternative to HRT and as a natural estrogenic source for
treatment has yet to be determined.
Although the biological effects of soy hold potential,
there are limitations, such as low bioavailability and low
biological estrogenic activity. This has limited the clinical
applications of genistein to some extent. However, the
components of soy are promising in terms of being a natural source of preventative care.
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